文献速递前列腺癌

≥75岁前列腺癌患者主动监测:PRIAS-JAPAN研究

Active surveillance for patients with prostate cancer aged ≥75 years: the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study.
PubMed 文献 · BJU Int · 2026-01-29

基于PRIAS-JAPAN前瞻性队列,比较≥75岁与<75岁局限期前列腺癌患者主动监测的结局。老年组10年癌症特异性生存与无转移生存均达100%,但主动监测持续率仅8.8%,总生存低于年轻组。提示部分高龄患者可以主动监测为结构化监测阶段,并计划减量过渡至观察等待。

要点

  • ≥75岁患者主动监测10年癌症特异性生存与无转移生存均为100%
  • 老年组10年主动监测持续率仅8.8%,多数转为其他管理
  • 高龄患者可以主动监测为监测阶段并计划减量过渡至观察等待

核心结论

  • 部分≥75岁前列腺癌患者以主动监测作为结构化监测阶段并计划减量过渡至观察等待,可在避免过度治疗的同时维持优异的肿瘤特异性结局。

研究设计与样本

  • PRIAS-JAPAN为全国多中心前瞻性队列研究,纳入临床局限期前列腺癌主动监测患者。
  • 截至2024年2月29日共纳入1274例,≥75岁老年组231例,<75岁年轻组1043例。
  • 原纳入标准为临床分期T1c-T2、PSA≤10 ng/mL、PSA密度<0.20 ng/mL/mL、Gleason评分≤3+3且阳性活检针数≤2。
  • 2021年起MRI应用扩大纳入标准至PSA≤20 ng/mL、PSA密度<0.25 ng/mL/mL、Gleason评分≤3+4且阳性活检针数<50%。
  • 监测方案为每3-6个月检测PSA,活检安排在第1、4、7、10年,此后每5年一次。

主要发现

  • 老年组入组中位年龄77岁,诊断时前列腺体积更大、Gleason评分3+4比例更高、T2期病变更多。
  • 方案活检接受率随时间下降:第一次82.9%、第二次63.6%、第三次42.2%、第四次22.4%,年龄组间无显著差异。
  • 老年组10年主动监测持续率为8.8%。
  • 老年组总生存显著低于年轻组(风险比0.32,95%置信区间0.14-0.74)。
  • 老年组10年无转移生存率和癌症特异性生存率均为100%。

关键数值与推荐

  • 原纳入标准:临床分期T1c-T2、PSA≤10 ng/mL、PSA密度<0.20 ng/mL/mL、Gleason评分≤3+3且阳性活检针数≤2。
  • 2021年扩大标准:PSA≤20 ng/mL、PSA密度<0.25 ng/mL/mL、Gleason评分≤3+4且阳性活检针数<50%。
  • PSA监测间隔3-6个月,活检在第1、4、7、10年及此后每5年。

临床怎么用

  • 对≥75岁局限期前列腺癌患者,可与患者共同决策,将主动监测作为结构化监测阶段。
  • 应预先规划监测减量与向观察等待的过渡,以避免过度治疗。
  • 需关注高龄患者总生存较低,但肿瘤特异性结局仍优异。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate clinical outcomes, treatment, and survival rates of men aged ≥75 years with prostate cancer in Japan. PATIENTS AND METHODS: The study used data from the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN, a nationwide, multicentre prospective cohort study of men with clinically localised prostate cancer managed with active surveillance (AS). The original eligibility criteria were clinical stage T1c-T2 disease, prostate-specific antigen (PSA) level ≤10 ng/mL, PSA density (PSAD) <0.20 ng/mL/mL, and Gleason Score ≤3 + 3 with two or fewer positive biopsy cores. In 2021, magnetic resonance imaging use expanded eligibility to include patients with a PSA level ≤20 ng/mL, PSAD <0.25 ng/mL/mL, and Gleason Score ≤3 + 4 with <50% of biopsy cores positive. PSA was monitored every 3-6 months, and biopsies were scheduled at 1, 4, 7, and 10 years, and every 5 years thereafter. The outcomes in those aged ≥75 years (older group) were compared with those aged <75 years (younger group). RESULTS: Of the 1274 eligible patients enrolled by 29 February 2024, 231 were in the older group and 1043 were in the younger group. In the older group, the median age at enrolment was 77 years. At diagnosis, patients in the older group had significantly larger prostate volumes, higher proportion of Gleason Score 3 + 4, and more T2 disease than those in the younger group. The protocol biopsy acceptance rate decreased over time (first: 82.9%, second: 63.6%, third: 42.2%, fourth: 22.4%), with no significant difference between age groups. The 10-year AS persistence rate in the older group was 8.8%. The overall survival was significantly lower in the older group than in the younger group (hazard ratio: 0.32, 95% confidence interval 0.14-0.74); however, the 10-year metastasis-free survival and cancer-specific survival rates in the older group were both 100%. CONCLUSION: In some patients aged ≥75 years an observation-focused management approach may be appropriate, in which AS is initiated as a structured monitoring phase with planned de-intensification and transition to watchful waiting, to prevent overtreatment while maintaining excellent cancer-specific outcomes.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kato T, Yokomizo A, Matsumoto R, et al. Active surveillance for patients with prostate cancer aged ≥75 years: the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study. BJU Int. 2026. PMID: 41609475. doi:10.1111/bju.70156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。